Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Change in Cash (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Change in Cash for 3 consecutive years, with $12.3 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Change in Cash rose 243.35% year-over-year to $12.3 million, compared with a TTM value of $45.4 million through Dec 2024, up 244.43%, and an annual FY2024 reading of $45.4 million, up 244.43% over the prior year.
  • Change in Cash was $12.3 million for Q4 2024 at Oramed Pharmaceuticals, up from -$42.6 million in the prior quarter.
  • Across five years, Change in Cash topped out at $66.2 million in Q2 2024 and bottomed at -$42.6 million in Q3 2024.
  • Average Change in Cash over 3 years is $2.2 million, with a median of $2.6 million recorded in 2022.
  • The sharpest move saw Change in Cash plummeted 3301.57% in 2023, then skyrocketed 481.71% in 2024.
  • Year by year, Change in Cash stood at $7.3 million in 2022, then crashed by 50.65% to $3.6 million in 2023, then soared by 243.35% to $12.3 million in 2024.
  • Business Quant data shows Change in Cash for ORMP at $12.3 million in Q4 2024, -$42.6 million in Q3 2024, and $66.2 million in Q2 2024.